| 鼠神经生长因子治疗急性脑梗死的临床疗效研究 |
| |
| 引用本文： | 杨帆,陈俊良,周格知,童民锋. 鼠神经生长因子治疗急性脑梗死的临床疗效研究[J]. 中华全科医学, 2018, 16(6): 903-905. DOI: 10.16766/j.cnki.issn.1674-4152.000247 |
| |
| 作者姓名： | 杨帆 陈俊良 周格知 童民锋 |
| |
| 作者单位： | 金华市中心医院神经外科, 浙江 金华 321000 |
| |
| 基金项目： | 浙江省科技计划项目(2013C33103)；浙江省医学会临床科研基金项目(2015ZYC-A91) |
| |
| 摘 要： | 目的 观察鼠神经生长因子治疗急性脑梗死的临床疗效。 方法 选取金华市中心医院2015年6月-2016年12月收治的100例脑梗死患者,随机分为治疗组50例和对照组50例。2组患者入组后均予基础治疗,包括抗血小板、调脂、控制血压血糖、康复训练,治疗组在此基础上给予鼠神经生长因子治疗,18 μg肌肉注射,1次/d,疗程4周。采用改良的Rankin量表(mRS),Barthel指数(BI)和美国国立卫生研究院卒中量表(NIHSS)比较2组患者2周及1个月后临床疗效。 结果 治疗2周后治疗组mRS和BI评分分别为2.75±0.19和46.22±5.41,对照组为3.12±0.23和42.95±6.72,差异均有统计学意义(P<0.05),治疗组优于对照组;治疗1个月后治疗组mRS和BI评分分别为2.23±0.15和59.56±4.28,对照组为2.78±0.18和53.21±6.45,差异均有统计学意义(P<0.05),治疗组优于对照组;治疗2周及1个月后,根据NIHSS评分,治疗组总有效率分别为84.0%和96.0%,对照组为66.0%和82.0%,治疗组疗效优于对照组,差异均有统计学意义(P<0.05)。 结论 采用常规治疗联合早期足疗程鼠神经生长因子方案,可明显改善患者的神经功能缺损症状,提高治疗的有效性。
|
| 关 键 词： | 脑梗死 鼠神经生长因子 临床疗效 安全性 |
| 收稿时间： | 2017-07-06 |
Clinical efficacy of mouse nerve growth factor in the treatment of acute cerebral infarction |
| |
| Affiliation: | Department of Neurosurgery, Jinhua Municipal Central Hospital, Jinhua, Zhejiang 321000, China |
| |
| Abstract: | Objective To evaluate the clinical efficacy of mouse nerve growth factor (NGF) in the treatment of acute cerebral infarction. Methods A total of 100 cases of acute cerebral infarction were included in this study and randomized divided into treatment group (n=50) and control group (n=50). All the included patients were given regular treatment, including antiplatelet, lipid-regulating, blood glucose and pressure controlling, rehabilitation. The patients in the treatment group were given NGF 18 μg for injection based on regular treatment, once a day, for 4 weeks. Two weeks and 1 month after the treatment, the date of clinical efficacy was compared between the two groups. The clinical efficacy was evaluated according to modified Rankin scale (mRs), Barthel index (BI) and National Institute of Heath Stroke Scale (NIHSS). Results Significant difference in mRs (2.75±0.19 vs. 3.12±0.23) and BI (46.22±5.41 vs. 42.95±6.72) were noted between the treatment group and control group after 2 weeks treatment (P<0.05). Significant difference in mRs (2.23±0.15 vs. 2.78±0.18) and BI (59.56±4.28 vs. 53.21±6.45) were noted between the treatment group and control group after 1 month treatment (P<0.05). The clinical efficacy in the treatment group was better than that in the control group, 84.0% vs.66.0% at two weeks, and 96.0% vs.82.0% at one month according to NIHSS. Conclusion Mouse nerve growth factor combined with regular treatment can significantly improve the neurological defects in the patients with acute cerebral infarction and improve the efficacy of the treatment. |
| |
| Keywords: | |
|
| 点击此处可从《中华全科医学》浏览原始摘要信息 |
|
点击此处可从《中华全科医学》下载免费的PDF全文 |
|
